Fullerton, CA December 16, 2003 Biomedical company Beckman Coulter says it has acquired the assets of Q3DM, including Q3DM’s cell imaging platform, software and cell imaging applications used in pharmaceutical research, cell analysis laboratories and universities. Under terms of the agreement, Q3DM will receive from Beckman Coulter a combination of cash and royalties on instrument sales. Further details were not disclosed.
"This addition to Beckman Coulter’s systems biology platform strengthens our cellular analysis solutions portfolio by allowing us to pursue opportunities for delivering novel cell-based assays," says Elias Caro, president of Beckman Coulter’s Biomedical Research Division. "Our past experience and current focus on research cellular analysis, combined with the successful launch of the FC 500 flow cytometer, have prepared us to aggressively pursue the cellular analysis market."
Beckman Coulter says it will begin selling the EIDAQ 100 high-throughput microscopy system immediately. In the coming years, Beckman Coulter plans to introduce new high throughput cellular imaging products utilizing Q3DM’s focusing technology and cellular image data mining software.